Last reviewed · How we verify
High-Dose Dexamethasone
High-dose dexamethasone is a potent synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
High-dose dexamethasone is a potent synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Acute inflammatory conditions, Autoimmune disorders, Cerebral edema.
At a glance
| Generic name | High-Dose Dexamethasone |
|---|---|
| Also known as | Corticosteroid, Dexamethasone sodium phosphate |
| Sponsor | Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno |
| Drug class | Glucocorticoid (corticosteroid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Dexamethasone acts as a glucocorticoid receptor agonist, translocating to the nucleus and modulating gene expression to decrease production of inflammatory mediators including TNF-α, IL-1, and IL-6. At high doses, it provides broad immunosuppression and anti-inflammatory effects, making it useful in acute inflammatory and autoimmune conditions. The drug also has mineralocorticoid activity at higher doses, affecting fluid and electrolyte balance.
Approved indications
- Acute inflammatory conditions
- Autoimmune disorders
- Cerebral edema
- Severe allergic reactions
- Adrenal insufficiency
Common side effects
- Hyperglycemia
- Insomnia
- Mood changes (euphoria, anxiety)
- Hypertension
- Immunosuppression/increased infection risk
- Osteoporosis (with chronic use)
- Gastrointestinal upset
- Hypokalemia
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (PHASE3)
- Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss (PHASE1, PHASE2)
- Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy (PHASE2)
- A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |